Transfer to long-acting buprenorphine from full opioid agonists in different dependent demographics: do’s, don’ts, and why does it matter?
Watch the autumn educational session led by Dr Michael Frost and joined by Professor Michael Soyka that discussed perspectives from both opioid-dependent treatment providers and patients surrounding use of long-acting buprenorphine (LAB) in different treatment scenarios and treatment journey stages. Furthermore, to share best practice approaches for transferring patients from daily dose methadone or buprenorphine to LAB, potential transfer outcomes and next steps.
After watching this webinar, viewers should be able to discuss
- Perspectives/experience from professionals and patients
- Experience in different treatment scenarios (stable patients versus [at-risk of becoming/] unstable patients)
- Transfer strategies to avoid (precipitated) withdrawal – micro-dosing
- LAB treatment optimisation during the switch / transfer and throughout ongoing treatment; and options for patients who find LAB unsuitable
Speaker – Professor Michael Soyka
Professor, Psychiatric Hospital, University of Munich, Germany
Chair – Dr Michael Frost
President/Medical Director, The Frost Medical Group, Pennsylvania, United States
The IOTOD webinar ‘Transfer to long-acting buprenorphine from full opioid agonists in different dependent demographics: do’s, don’ts, and why does it matter?’is supported by grant funding from Camurus. The educational programme is run at arm’s length from the financial supporters and all content is created by the faculty. No funder has had input into the content of the materials or presentations used in the educational programme. PCM Scientific is the medical education company acting as scientific secretariat and webinar organiser.